Buy
Original-Research: Epti AB - von GBC AG
Einstufung von GBC AG zu Epti AB
Unternehmen: Epti AB
ISIN: SE0013774668
Anlass der Studie: Research Comment
Empfehlung: Buy
Kursziel: 0.80 EUR
Kursziel auf Sicht von: 31.12.2023
Letzte Ratingänderung:
Analyst: Matthias Greiffenberger, Cosmin Filker
Significant growth with strong earnings improvements in the 3rd quarter
In the third quarter of 2022, EPTI AB increased sales by 134.7% to SEK
53.74 M (PY: SEK 22.90 M). Consequently, sales in the first nine months of
2022 almost quadrupled year-on-year by 286.9% to SEK 155.2 million (PY: SEK
40.11 million). Of the nine-month revenue, SEK 125.69 million was
attributable to EPTI Service AB and SEK 48.72 million to EPTI Invest AB.
Total output increased by 51.4% to SEK 57.23 million (PY: SEK 37.79
million) in the third quarter of 2022, which corresponds to an increase of
172.9% to SEK 174.41 million (PY: SEK 63.91 million) on a nine-month basis.
EPTI Invest AB accounted for SEK 8.34 million (PY: SEK 18.46 million) of
the total operating performance and EPTI Service AB for SEK 48.89 million
(PY: SEK 19.34 million). The reason for the decrease in EPTI Invest's total
operating performance is due to the lower number of consolidated
investments. Thus, the investments are recorded as associated companies and
are no longer consolidated.
EBITDA amounted to SEK 4.78 million in the third quarter of 2022 (PY: €
12.41 million). The year-on-year reduction is attributable to highly
positive one-off effects from the previous year. In a nine-month view,
EBITDA decreased to SEK -6.68 million (PY: SEK 11.75 million). EPTI Service
AB contributed EBITDA of € 27.44 million, while the
EPTI Invest's EBITDA was SEK -11.00 million and that of the Group's parent
company was SEK -23.12 million.
Depreciation and amortization increased to SEK 10.48 million (PY: SEK 3.12
million), of which SEK 9.68 million was attributable to goodwill
amortization. The reason for this is the amortization of goodwill acquired
as part of the reverse IPO. The non-consolidated companies resulted in
negative financial expenses of SEK -4.16 million (PY: SEK 0.92 million).
Consequently, the total net result was SEK -73.25 million (PY: SEK 3.36
million).
According to our revaluation of EPTI Services and Apotekamo as well as the
warrants, we have determined a positive valuation discrepancy (hidden
reserves) in the amount of SEK 226.52 million. The valuation discrepancy in
addition to the NAV of SEK 715.59 million determined as of September 30,
2022, results in a total NAV according to the GBC valuation approach of SEK
942.12 million (previously: SEK 952.67 million).
At the current price of € 0.21 (Xetra, 17.11.22 17:35), this means a
significant upside potential of 281% and therefore we assign a BUY rating.
Even if we only consider the NAV on a K3 basis of SEK 715.59 million, this
would result in a NAV per share of SEK 6.70 or € 0.61 per share, which also
represents an enormous upside potential to the current share price of
190.5%.
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/26167.pdf
Kontakt für RückfragenOffenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,6a,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:
http://www.gbc-ag.de/de/Offenlegung.htm
+++++++++++++++
Datum (Uhrzeit) der Fertigstellung: 12.12.2022 (13:50 Uhr)
Datum (Uhrzeit) der ersten Veröffentlichung: 13.12.2022 (10:00 Uhr)
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.